Fulcrum Therapeutics (FULC) Insider Trading & Ownership $3.26 +0.05 (+1.56%) (As of 11/4/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Fulcrum Therapeutics (NASDAQ:FULC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.10%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$59,071.84 Get FULC Insider Trade Alerts Want to know when executives and insiders are buying or selling Fulcrum Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address FULC Insider Buying and Selling by Quarter Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Fulcrum Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/7/2024Greg TourangeauInsiderSell236$7.76$1,831.36 3/8/2024Greg TourangeauVPSell4,884$11.72$57,240.48 (Data available from 1/1/2013 forward) FULC Insider Trading Activity - Frequently Asked Questions Who is on Fulcrum Therapeutics's Insider Roster? The list of insiders at Fulcrum Therapeutics includes Greg Tourangeau, Ra Capital Management, L.P., Robert J Gould. Learn more on insiders at FULC. What percentage of Fulcrum Therapeutics stock is owned by insiders? 4.10% of Fulcrum Therapeutics stock is owned by insiders. Learn more on FULC's insider holdings. Which Fulcrum Therapeutics insiders have been buying company stock? The following insider purchased FULC shares in the last 24 months: Ra Capital Management, L.P. ($38,695,654.65). How much insider buying is happening at Fulcrum Therapeutics? Insiders have purchased a total of 4,372,675 FULC shares in the last 24 months for a total of $38,695,654.65 bought. Which Fulcrum Therapeutics insiders have been selling company stock? The following insiders have sold FULC shares in the last 24 months: Greg Tourangeau ($59,766.94), and Robert J Gould ($101,490.00). How much insider selling is happening at Fulcrum Therapeutics? Insiders have sold a total of 12,096 Fulcrum Therapeutics shares in the last 24 months for a total of $161,256.94 sold. More Insider Trading Tools from MarketBeat Related Companies BLUE Insider Trading KZR Insider Trading SGMO Insider Trading CRON Insider Trading RLAY Insider Trading ANNX Insider Trading ERAS Insider Trading IMNM Insider Trading TRML Insider Trading ORIC Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Big Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside This page (NASDAQ:FULC) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
